Skip to main content

Clinical trials

Current and upcoming trials

We’re an internationally certified clinical trial unit, conducting clinical trials in eye genetics and inherited retinal diseases. 

Our clinical trials are conducted according to the strict guidelines of the ICH GCP (International Conference on the Harmonisation of Good Clinical Practice) and our staff are experienced and internationally certified in vision assessments and retinal imaging procedures. Study staff maintain current certifications across multiple reading centres worldwide in all retinal imaging procedures including optical coherence tomography, fundus autofluorescence and retinal photography.

Therapies are becoming available for inherited retinal diseases (IRD). IRD in general progress slowly over time often with declines in function followed by long period of stability. To be able to detect if potential therapies are effective there is a need for an understanding of he disease progress in individuals. The Eye genetics and Inherited retinal disease group have developed clinical protocols in collaboration with international and local centres to standardise these assessments.

Trials

Nacuity Safety and Efficacy of NPI-001 Tablets versus Placebo for Treatment of Retinitis Pigmentosa Associated with Usher Syndrome.

Find out more.

This study is assessing the economic impact of living with an inherited retinal disease.

This study is assessing the clinical function in people with Stargardt disease utilising advanced multimodal imaging and visual functional studies.

This study is assessing the clinical function in people with cone-rod or once dystrophy utilising advanced multimodal imaging and visual functional studies.

This study is assessing the clinical function in people with Achromatopsia utilising advanced multimodal imaging and visual functional studies.

This study is assessing the clinical function in people with Retinitis Pigmentosa utilising advanced multimodal imaging and visual functional studies.

Stargardt Disease study -Protocol Number: LBS-008-CT03

Title: Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects

The study objective is to determine whether VR mobility assessment tool parameters can serve as biomarkers of functional vision in participants with retinal disease

Robyn Jamieson

Professor John Grigg

Save Sight Institute

Address
  • South Block, Sydney Eye Hospital 8 Macquarie Street Sydney NSW 2000